Spots Global Cancer Trial Database for safety profile
Every month we try and update this database with for safety profile cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) | NCT02260505 | Gastrointestina... Resected Gastro... Non-metastatic High Risk of Re... KIT Gene Mutati... | Imatinib mainte... | 18 Years - | Centre Leon Berard | |
Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia | NCT02316197 | Advanced Solid ... Chronic Lymphoc... | MSC2490484A (M3... | 18 Years - | Merck KGaA, Darmstadt, Germany | |
Faslodex Post Marketing Surveillance | NCT00860561 | Breast Cancer | - | AstraZeneca | ||
Faslodex Post Marketing Surveillance | NCT00860561 | Breast Cancer | - | AstraZeneca | ||
Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) | NCT02014831 | Squamous Cell C... | Cetuximab TIP | 18 Years - | Centre Leon Berard |